Compare XENE & INSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XENE | INSP |
|---|---|---|
| Founded | 1996 | 2007 |
| Country | Canada | United States |
| Employees | N/A | 1246 |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 2.8B |
| IPO Year | 2014 | 2018 |
| Metric | XENE | INSP |
|---|---|---|
| Price | $42.43 | $98.00 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 17 |
| Target Price | $53.91 | ★ $137.63 |
| AVG Volume (30 Days) | 857.1K | ★ 1.8M |
| Earning Date | 02-26-2026 | 02-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 34.77 |
| EPS | N/A | ★ 1.48 |
| Revenue | $7,500,000.00 | ★ $882,622,000.00 |
| Revenue This Year | N/A | $15.00 |
| Revenue Next Year | N/A | $11.24 |
| P/E Ratio | ★ N/A | $65.85 |
| Revenue Growth | N/A | ★ 16.81 |
| 52 Week Low | $26.74 | $70.77 |
| 52 Week High | $46.60 | $216.01 |
| Indicator | XENE | INSP |
|---|---|---|
| Relative Strength Index (RSI) | 44.90 | 45.06 |
| Support Level | $40.41 | $90.49 |
| Resistance Level | $46.36 | $97.00 |
| Average True Range (ATR) | 1.59 | 4.42 |
| MACD | -0.43 | -1.42 |
| Stochastic Oscillator | 30.35 | 29.92 |
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and Europe wherein, it generates a majority of its revenue from the United States.